| 1 |
NCT00742300 |
Unknown † |
Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases |
|
- Procedure: Autologous hematopoietic stem cell transplantation
|
Interventional
|
Phase 1
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall Survival
- Immune Reconstitution
- (and 2 more...)
|
|
All |
18 Years to 60 Years (Adult) |
NCT00742300 |
CT-0198 |
ASTRAD |
January 1998 |
|
|
August 27, 2008 |
November 24, 2008 |
|
- Charité Universitätsmedizin Berlin
Berlin, Germany
|
|
| 2 |
NCT00849745 |
Terminated |
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases |
- Systemic Lupus Erythematosus
- Systemic Sclerosis
|
- Procedure: Nonmyeloablative allogeneic stem cell transplant
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Engraftment
- Graft versus Host Disease
- Toxicity
- (and 5 more...)
|
4 |
All |
18 Years to 69 Years (Adult, Older Adult) |
NCT00849745 |
Pro00010324 |
|
January 2003 |
July 2015 |
July 2015 |
February 24, 2009 |
June 23, 2016 |
|
- Duke University Health System
Durham, North Carolina, United States
|
|
| 3 |
NCT00010335 |
Completed |
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders |
- Systemic Sclerosis
- Systemic Lupus Erythematosus
- Dermatomyositis
- (and 2 more...)
|
- Procedure: Stem Cell Transplantation
- Device: CD34 selection
|
Interventional
|
Phase 1 |
- Fred Hutchinson Cancer Research Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mortality
- Immune reconstitution, engraftment, efficacy, late-effects
|
6 |
All |
2 Years to 18 Years (Child, Adult) |
NCT00010335 |
1353.00
FHCRC-1353.00
199/15575 |
|
November 2000 |
July 2010 |
May 2011 |
February 2, 2001 |
March 6, 2015 |
|
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
|
|
| 4 |
NCT01540292 |
Unknown † |
Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders |
|
- Biological: Mesenchymal Stem Cells (MSC)
|
Interventional
|
Phase 1
Phase 2 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response Rate
- Clinical Response
- Remission
- (and 5 more...)
|
20 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01540292 |
TJT1123 |
|
March 2012 |
June 2016 |
June 2017 |
February 28, 2012 |
January 21, 2013 |
|
- University Hospital Liège
Liège, Belgium
|
|
| 5 |
NCT00716066 |
Recruiting |
Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy |
|
- Biological: Anti-Thymocyte Globulin
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Carmustine
- (and 7 more...)
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of grades 4-5 regimen-related toxicity as assessed by the Regimen Related Toxicity Scale
- Disease responses as assessed by clinical, laboratory and radiologic evaluation
- Engraftment kinetics
- (and 3 more...)
|
40 |
All |
up to 70 Years (Child, Adult, Older Adult) |
NCT00716066 |
2260.00
NCI-2010-00403
P30CA015704 |
|
June 2008 |
March 31, 2020 |
December 1, 2021 |
July 16, 2008 |
December 18, 2018 |
|
- Colorado Blood Cancer Institute
Denver, Colorado, United States - Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States - Swedish Medical Center-First Hill
Seattle, Washington, United States
|
|
| 6 |
NCT01099930 |
Completed |
Autologous Stem Cell Transplant for Multiple Sclerosis |
|
- Other: immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),
- Other: Standard Therapy
|
Interventional
|
Phase 2 |
- Ottawa Hospital Research Institute
- Multiple Sclerosis Scientific Research Foundation
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 3 year MS activity free survival
- Transplant related morbidity
- Transplant related mortality
- (and 2 more...)
|
24 |
All |
18 Years to 50 Years (Adult) |
NCT01099930 |
200037401H |
MS/BMT |
August 2001 |
November 2012 |
June 2016 |
April 8, 2010 |
September 28, 2016 |
|
- Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
|
|
| 7 |
NCT01673789 |
Unknown † |
Stem Cell Educator Therapy in Alopecia Areata |
|
- Device: Stem Cell Educator
|
Interventional
|
Phase 1
Phase 2 |
- Tianhe Stem Cell Biotechnologies Inc.
- The First Hospital of Hebei Medical University
- Tianhe Stem Cell Biotechnologies Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility and efficacy of Stem Cell Educator therapy in AA
- The efficacy of Stem Cell Educator therapy in modulating autoimmunity
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01673789 |
2012-TH01 |
|
August 2012 |
July 2013 |
July 2013 |
August 28, 2012 |
August 28, 2012 |
|
- The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
|
|
| 8 |
NCT02516124 |
Completed |
EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc Patients |
|
- Procedure: Autologous HSCT
|
Observational
|
|
- European Group for Blood and Marrow Transplantation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression free survival
- Safety assessed by Treatment related toxicity throughout the study period using WHO toxicity parameters (expressed as maximum grade toxicity per organ system, see appendix)
- Overall Survival
- (and 4 more...)
|
82 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02516124 |
|
NISSC |
December 2012 |
January 2018 |
March 2018 |
August 5, 2015 |
May 1, 2018 |
|
- Badoglio Manuela- EBMT Paris Office
Paris, France
|
|
| 9 |
NCT02264405 |
Unknown † |
Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study |
|
- Procedure: Autologous HSCT
|
Observational
|
|
- European Group for Blood and Marrow Transplantation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression free survival
- Safety
- Overall Survival
- (and 4 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02264405 |
EBMT-8410015 |
NISSC |
December 2012 |
December 2015 |
December 2017 |
October 15, 2014 |
October 20, 2014 |
|
- Badoglio Manuela- EBMT Paris Office
Paris, France
|
|
| 10 |
NCT03444805 |
Not yet recruiting |
EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2) |
|
- Procedure: Autologous HSCT
|
Observational
|
|
- European Group for Blood and Marrow Transplantation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression free survival (PFS),
- Treatment related toxicity
- 100 days Treatment Related Mortality (100d TRM)
- (and 8 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03444805 |
ADWP 8410025 |
NISSC-2 |
June 1, 2018 |
December 31, 2019 |
March 30, 2020 |
February 23, 2018 |
May 1, 2018 |
|
- Badoglio Manuela- EBMT Paris Office
Paris, France
|
|
| 11 |
NCT01322789 |
Unknown † |
Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients |
- Diabetes Mellitus, Insulin-Dependent
|
- Biological: Intravenous Mesenchymal stem cell infusion
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- AUC C-peptide levels during mixed meal tolerance test
- Safety
- Daily insulin use
- (and 3 more...)
|
10 |
All |
12 Years to 35 Years (Child, Adult) |
NCT01322789 |
HCFMRPUSP 2
CNPQ 552266/2005-1 |
|
September 2008 |
November 2015 |
December 2015 |
March 25, 2011 |
March 25, 2011 |
|
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Ribeirão Preto, São Paulo, Brazil
|
|
| 12 |
NCT02644759 |
Completed |
Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus |
- Diabetes Mellitus Type 1
- Autoimmune Diseases
- Endocrine System Diseases
- (and 3 more...)
|
- Biological: Stem Cell Transplantation
|
Interventional
|
Phase 1
Phase 2 |
- Stem Cells Arabia
- Stem Cells Arabia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Exogenous insulin dose
- Anti-GAD titres
- C-peptide level
- HbA1c level
|
100 |
All |
8 Years to 55 Years (Child, Adult) |
NCT02644759 |
SCA-DM1 |
|
February 2014 |
August 2017 |
May 2018 |
January 1, 2016 |
June 6, 2018 |
|
- Stem Cells Arabia
Amman, Jordan
|
|
| 13 |
NCT00273364 |
Active, not recruiting |
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study |
|
- Procedure: Hematopoietic Stem Cell Therapy
- Drug: Standard treatment with a conventional drug
|
Interventional
|
Phase 2 |
- Northwestern University
- Uppsala University
- Sheffield Teaching Hospitals NHS Foundation Trust
- University of Sao Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Expanded Disability Status Scale (EDSS) Improvement
|
110 |
All |
18 Years to 55 Years (Adult) |
NCT00273364 |
DI MS.Randomized2004 |
|
November 16, 2005 |
February 2018 |
December 2018 |
January 9, 2006 |
July 16, 2018 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 14 |
NCT02282514 |
Active, not recruiting |
Stem Cell Transplantation for Stiff Person Syndrome (SPS) |
|
- Biological: Autologous Hematopoietic Stem Cells
- Drug: Cyclophosphamide
- Drug: Mesna
- (and 4 more...)
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Reduction of muscle relaxation anti-spasmatic medications
- Improvement of Chronic Pain Acceptance Questionnaire (CPAQ)
- (and 4 more...)
|
23 |
All |
18 Years to 60 Years (Adult) |
NCT02282514 |
DIAD.SPS.2014 |
SPS |
October 2014 |
October 2020 |
October 2021 |
November 4, 2014 |
January 31, 2019 |
|
- Northwestern University
Chicago, Illinois, United States
|
|
| 15 |
NCT02824393 |
Completed |
Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria |
- Urticaria
- Autoimmune Diseases
- Immune System Diseases
- Skin Diseases
|
- Biological: Autologous mesenchymal stem cell
|
Interventional
|
Early Phase 1 |
- Celal Bayar University
- The Scientific and Technological Research Council of Turkey
- Acıbadem Labcell
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in weekly urticaria activity scores.
- Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.
- The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.
- (and 2 more...)
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02824393 |
TUBITAK-1001-215S612 |
|
March 3, 2017 |
May 15, 2018 |
July 15, 2018 |
July 6, 2016 |
July 18, 2018 |
|
- Celal Bayar University, Medical School
Manisa, Turkey
|
|
| 16 |
NCT01996228 |
Recruiting |
Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy |
|
- Device: Stem Cell Educator
|
Interventional
|
Phase 1
Phase 2 |
- Tianhe Stem Cell Biotechnologies Inc.
- Second Xiangya Hospital of Central South University
- Tianhe Stem Cell Biotechnologies Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Autoimmune control
- Metabolic control
|
20 |
All |
6 Years to 14 Years (Child) |
NCT01996228 |
2013-0002 |
|
November 2013 |
October 2019 |
October 2019 |
November 27, 2013 |
February 5, 2019 |
|
- The Second Xiangya Hospital
Changsha, Hunan, China
|
|
| 17 |
NCT00278538 |
Active, not recruiting |
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus |
- Systemic Lupus Erythematosus
|
- Biological: Hematopoietic stem cell transplantation
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
33 |
All |
15 Years to 60 Years (Child, Adult) |
NCT00278538 |
DI SLE.Auto2003 |
|
September 23, 2005 |
February 2018 |
December 2018 |
January 18, 2006 |
July 16, 2018 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States - Northwestern University
Chicago, Illinois, United States
|
|
| 18 |
NCT00006055 |
Unknown † |
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases |
- Purpura, Schoenlein-Henoch
- Graft Versus Host Disease
- Anemia, Hemolytic, Autoimmune
- (and 11 more...)
|
- Drug: anti-thymocyte globulin
- Drug: cyclophosphamide
- Drug: cyclosporine
- (and 4 more...)
|
Interventional
|
Not Applicable |
- Fairview University Medical Center
- Office of Rare Diseases (ORD)
|
Other |
- Primary Purpose: Treatment
|
|
10 |
All |
1 Year to 55 Years (Child, Adult) |
NCT00006055 |
199/15105
UMN-MT-1996-15
UMN-MT-9615 |
|
March 2000 |
|
|
July 6, 2000 |
June 24, 2005 |
|
- Fairview University Medical Center
Minneapolis, Minnesota, United States
|
|
| 19 |
NCT01341899 |
Completed |
Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes |
|
- Procedure: immunosuppression and stem cell transplantation
|
Interventional
|
Phase 2 |
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation
- Changes in serum levels of HbA1c from baseline to different time points after transplantation
- Temporal changes of exogenous insulin requirement from baseline to different time points after transplantation
- (and 3 more...)
|
50 |
All |
8 Years to 35 Years (Child, Adult) |
NCT01341899 |
ZKX07012 |
|
June 2006 |
December 2012 |
December 2015 |
April 26, 2011 |
November 1, 2016 |
|
- at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
Nanjing, Jiangsu, China
|
|
| 20 |
NCT00114530 |
Completed
Has Results |
Scleroderma: Cyclophosphamide or Transplantation (SCOT) |
- Scleroderma, Systemic
- Sclerosis
- Autoimmune Disease
|
- Biological: mHSCT
- Drug: cyclophosphamide
|
Interventional
|
Phase 2
Phase 3 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Global Rank Composite Score (GRCS) (Month 54, ITT)
- Global Rank Composite Score (GRCS) (Month 54, PP)
- Global Rank Composite Score (GRCS) (Month 48, ITT)
- (and 38 more...)
|
75 |
All |
18 Years to 69 Years (Adult, Older Adult) |
NCT00114530 |
DAIT SCSSc-01
SCOT |
|
June 2005 |
April 2016 |
April 2016 |
June 16, 2005 |
January 29, 2018 |
July 14, 2017 |
- City of Hope National Medical Center
Duarte, California, United States - UCLA Medical School
Los Angeles, California, United States - University of Kentucky
Lexington, Kentucky, United States - (and 14 more...)
|
|
| 21 |
NCT02249676 |
Completed |
Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders |
- Devic's Syndrome
- Devic's Neuromyelitis Optica
- Devic Syndrome
- (and 2 more...)
|
- Biological: Autologous mesenchymal stem cells
|
Interventional
|
Phase 2 |
- Tianjin Medical University General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- EDSS
- Annual relapse rate
- Lesion load
- (and 4 more...)
|
15 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02249676 |
IRB2013-055-02 |
|
January 2013 |
December 31, 2014 |
December 31, 2014 |
September 25, 2014 |
October 17, 2018 |
|
- Tianjin Medical University General Hospital
Tianjin, Tianjin, China
|
|
| 22 |
NCT01350219 |
Recruiting |
Stem Cell Educator Therapy in Type 1 Diabetes |
|
- Device: Stem Cell Educator
|
Interventional
|
Phase 2 |
- Tianhe Stem Cell Biotechnologies Inc.
- Chinese government fundings
- Tianhe Stem Cell Biotechnologies Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Autoimmune control
- Metabolic control
- Analysis of islet beta cell function
|
100 |
All |
14 Years to 60 Years (Child, Adult) |
NCT01350219 |
2010-037 |
|
September 2010 |
September 2019 |
September 2019 |
May 9, 2011 |
February 5, 2019 |
|
- The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China - The Second Xiangya Hospital of Central South University
Changsha, Hunan, China - General Hospital of Jinan Military Command
Jinan, Shandong, China - Hospital Universitario Central de Asturias
Oviedo, Asturias, Spain
|
|
| 23 |
NCT02741362 |
Terminated |
Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome |
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Sharp's Syndrome
|
- Other: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs
- Other: Lipoaspiration
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of Adverse Events (AE) and Serious Adverse Events (SAE) during a 6 month follow up period.
- Quality of Life Questionnaires for SLE/ RA
- Quality of Life Questionnaires for RA
- (and 8 more...)
|
2 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02741362 |
ICMS-2015-51 |
|
December 2015 |
December 31, 2016 |
December 31, 2016 |
April 18, 2016 |
March 3, 2017 |
|
- Arkansas Heart Hospital
Little Rock, Arkansas, United States
|
|
| 24 |
NCT02674217 |
Enrolling by invitation |
Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells |
|
- Procedure: Hematopoietic stem cell transplantation
|
Interventional
|
Not Applicable |
- Centro de Hematología y Medicina Interna
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Expanded Disability Status Scale
- Overall survival
|
1000 |
All |
Child, Adult, Older Adult |
NCT02674217 |
CentroHMI
U1111-1195-1632 |
|
May 2015 |
December 2020 |
December 2020 |
February 4, 2016 |
January 31, 2019 |
|
|
|
| 25 |
NCT02225795 |
Withdrawn |
Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease. |
|
- Other: Hematopoietic stem cell transplantation
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the feasibility and toxicity of immunoablation with HSCT and post-HSCT infusion of cyclophosphamide in children and young adults with refractory Crohn's disease (CD).
- 1. Incidence of viral reactivations - CMV and EBV
- 2. Incidence of invasive fungal infections
- (and 2 more...)
|
0 |
All |
10 Years to 30 Years (Child, Adult) |
NCT02225795 |
BMT 12 |
|
August 2014 |
August 2019 |
December 2019 |
August 26, 2014 |
February 7, 2018 |
|
|
|
| 26 |
NCT01873625 |
Completed |
Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis |
|
- Biological: mesenchymal cell transplantation
- Biological: placebo
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- pain
- physical activity
- walking distance
- Imaging
|
60 |
All |
10 Years to 65 Years (Child, Adult, Older Adult) |
NCT01873625 |
Royan-RA-001 |
|
October 2009 |
March 2011 |
December 2011 |
June 10, 2013 |
June 10, 2013 |
|
- Royan Institute
Tehran, Iran, Islamic Republic of
|
|
| 27 |
NCT01730547 |
Unknown † |
Mesenchymal Stem Cells for Multiple Sclerosis |
|
- Biological: Autologous mesenchymal stem cells
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.
- To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).
|
15 |
All |
18 Years to 50 Years (Adult) |
NCT01730547 |
MSC-MS |
|
February 2013 |
December 2015 |
December 2015 |
November 21, 2012 |
January 15, 2015 |
|
- Karolinska Institute, Karolinska University Hospital Solna
Stockholm, Sweden
|
|
| 28 |
NCT00424489 |
Terminated
Has Results |
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis |
|
- Biological: Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: ATG (rabbit)
- (and 3 more...)
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
9 |
All |
15 Years to 65 Years (Child, Adult, Older Adult) |
NCT00424489 |
Myasthenia Gravis Auto 2002 |
|
February 2002 |
June 2016 |
June 2016 |
January 19, 2007 |
August 31, 2018 |
August 6, 2018 |
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 29 |
NCT01362179 |
Active, not recruiting |
National Marrow Donor Program Long-Term Donor Follow-Up |
|
|
Observational
|
|
- Center for International Blood and Marrow Transplant Research
- National Marrow Donor Program
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Incidence of malignant myeloid hematologic disorders
|
21932 |
All |
18 Years to 60 Years (Adult) |
NCT01362179 |
LTDFU |
LTDFU |
October 2010 |
September 30, 2020 |
September 30, 2020 |
May 30, 2011 |
August 23, 2018 |
|
- City of Hope
Duarte, California, United States - National Marrow Donor Program Northern California & Northwest District
Oakland, California, United States - National Marrow Donor Program Southern California & Southwest District
Santa Ana, California, United States - (and 26 more...)
|
|
| 30 |
NCT00076752 |
Completed
Has Results |
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus |
- Lupus Erythematosus, Systemic
|
- Drug: fludarabine phosphate
- Drug: cyclophosphamide
- Biological: Rituxan (rituximab)
- (and 7 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse-free Complete Clinical Response
- Number of Participants With Adverse Events
- Anti-Nuclear Antibody
- (and 13 more...)
|
9 |
All |
15 Years to 40 Years (Child, Adult) |
NCT00076752 |
040095
04-C-0095 |
|
January 30, 2004 |
October 15, 2013 |
October 15, 2013 |
February 3, 2004 |
May 2, 2017 |
June 10, 2014 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 31 |
NCT01378182 |
Completed |
Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis |
|
- Genetic: allogeneic mesenchymal stem cell transplantation
|
Interventional
|
Not Applicable |
- Murat Kantarcioglu
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01378182 |
110S153 |
|
April 2011 |
March 2013 |
December 2014 |
June 22, 2011 |
December 31, 2014 |
|
- Department of Gastroenterology; Gulhane Military Medical Academy
Ankara, Turkey
|
|
| 32 |
NCT02972801 |
Recruiting |
Testicular Tissue Cryopreservation for Fertility Preservation |
- Cancer
- Autoimmune Disorders
|
- Procedure: Testicular biopsy
|
Interventional
|
Not Applicable |
- University of Pittsburgh
- Children's Research Institute
- Children’s Hospital of Orange County
- (and 3 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Presence of spermatogonial stem cells in the testicular tissue as determined by histology.
|
250 |
Male |
Child, Adult, Older Adult |
NCT02972801 |
PRO09120485 |
|
January 2010 |
January 2021 |
January 2021 |
November 23, 2016 |
January 3, 2019 |
|
- Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States
|
|
| 33 |
NCT01297972 |
Completed |
Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia |
|
- Biological: Intravenous bone marrow mesenchymal stem cells infusion
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.
- Level of cytopenias
- Transfusional requirements
- Incidence of infections and febrile neutropenia
|
9 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01297972 |
CONEP 16119 |
|
February 2011 |
November 2013 |
November 2013 |
February 17, 2011 |
February 4, 2014 |
|
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Ribeirão Preto, São Paulo, Brazil
|
|
| 34 |
NCT01339455 |
Terminated |
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica |
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion relapse-free at three years
- Proportion relapse-free at five years
- Relapse count
- (and 7 more...)
|
3 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01339455 |
CHREB ID# 23282 |
SCT-NMO |
March 2011 |
March 2017 |
March 2017 |
April 20, 2011 |
May 2, 2018 |
|
- Foothills Medical Centre, University of Calgary
Calgary, Alberta, Canada
|
|
| 35 |
NCT01056471 |
Completed |
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis |
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Diseases
- (and 3 more...)
|
- Other: Autologous mesenchymal stem cells from adipose tissue.
|
Interventional
|
Phase 1
Phase 2 |
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Carlos III Health Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells
- To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01056471 |
CMM/EM/2008 |
|
January 2010 |
June 2012 |
June 2015 |
January 26, 2010 |
August 7, 2015 |
|
- Hospital Regional Universitario de Málaga
Málaga, Spain - Hospital Universitario Virgen Macarena
Sevilla, Spain
|
|
| 36 |
NCT03182426 |
Recruiting |
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) |
- Diabetes Mellitus, Type 1
|
- Drug: Plerixafor
- Drug: Alemtuzumab
- Drug: Anakinra
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- University of Alberta
- Alberta Innovates Health Solutions
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of 2-hour mixed meal stimulated C-peptide AUC
- Rate of Serious Adverse Event/Medical Event of Special Interest
- "Responder" status
- (and 8 more...)
|
60 |
All |
18 Years to 45 Years (Adult) |
NCT03182426 |
Pro00053082 |
|
August 15, 2017 |
August 30, 2022 |
December 31, 2022 |
June 9, 2017 |
July 24, 2018 |
|
- University of Alberta
Edmonton, Alberta, Canada
|
|
| 37 |
NCT00684255 |
Terminated
Has Results |
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) |
- Systemic Lupus Erythematosus
- Systemic Sclerosis
|
- Procedure: Reduced Intensity Allogeneic Transplant
- Drug: Fludarabine
- Drug: Busulfan
- Drug: Campath
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity
- Chimerism
- Immune Reconstitution.
- Progression Free and Overall Survival.
|
1 |
All |
7 Years to 50 Years (Child, Adult) |
NCT00684255 |
AAAB1324
CHNY-01-511 |
|
August 2007 |
July 2008 |
July 2008 |
May 26, 2008 |
April 1, 2014 |
December 2, 2009 |
- Columbia University Medical Center
New York, New York, United States
|
|
| 38 |
NCT02676622 |
Withdrawn |
Autologous Stem Cell Transplant for Refractory Crohn's Disease |
|
- Drug: mobilization of stem cells to prepare for Leukapheresis
- Other: Leukapheresis- Collection of stem cells
- Drug: Preparative regimen 4-6 weeks after Leukapheresis
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Nationwide Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint of the study is feasibility and safety of the autologous HSCT and low dose IL-2 post-HSCT, as evaluated by day +100 TRM (transplant related mortality) and incidence of severe toxicity.
- Secondary endpoints are evaluations of the effects of HSCT on clinical and laboratory manifestations of Crohn's Disease, i.e. frequency of and types of transplant related complications that were observed.
|
0 |
All |
12 Years to 29 Years (Child, Adult) |
NCT02676622 |
IRB1100448 |
|
April 2013 |
April 2013 |
April 2013 |
February 8, 2016 |
February 3, 2017 |
|
|
|
| 39 |
NCT01668576 |
Terminated |
Properties of Mesenchymal Stem Cells in Lung Transplant |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Intrinsic variability of MSCs measured by time to third passage of confluent MSC
- 2-3 IDO production measured as ug/mL of passage 3 MSCs
- Percent specific inhibition of CD4 and CD8 T cell proliferation toward donor target cells in one way mixed-lymphocyte reactions
|
4 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01668576 |
IRB00053075 |
|
August 2012 |
September 2014 |
September 2014 |
August 20, 2012 |
January 14, 2016 |
|
- Emory University
Atlanta, Georgia, United States
|
|
| 40 |
NCT03673748 |
Not yet recruiting |
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells |
- Lupus Nephritis
- Lupus Erythematosus
|
- Drug: Mesenchymal stromal cells (MSC)
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Red de Terapia Celular
- Hospital del Río Hortega
- Hospital Clínico Universitario de Valladolid
- University of Valladolid
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Frequency of severe adverse events
- Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)
- Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)
- (and 3 more...)
|
36 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03673748 |
TerCel_006
2017-000391-28 |
MSV_LE |
January 2019 |
December 2021 |
December 2021 |
September 17, 2018 |
September 17, 2018 |
|
- University Hospital Río Hortega
Valladolid, Spain
|
|
| 41 |
NCT02035514 |
Completed |
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis |
- Relapsing Remitting Multiple Sclerosis (RRMS)
|
- Biological: Bone marrow autologous mesenchymal stem cells transplantation
|
Interventional
|
Phase 1
Phase 2 |
- Germans Trias i Pujol Hospital
- Ministerio de Sanidad, Servicios Sociales e Igualdad
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in safety
- Change from baseline in effectiveness by MRI
- Feasibility
- (and 4 more...)
|
9 |
All |
18 Years to 50 Years (Adult) |
NCT02035514 |
CELLTRiMS
2010-024081-21 |
|
December 2013 |
July 2016 |
July 2016 |
January 14, 2014 |
December 15, 2016 |
|
- Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
|
|
| 42 |
NCT00315133 |
Completed |
Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus |
|
- Procedure: Immunosuppression and autologous stem cell transplantation
|
Interventional
|
Phase 1
Phase 2 |
- University of Sao Paulo
- Northwestern University
- Genzyme, a Sanofi Company
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- C-peptide levels
- Transplant-related toxicity
- Anti-GAD titres
- (and 4 more...)
|
25 |
All |
12 Years to 35 Years (Child, Adult) |
NCT00315133 |
HCFMRPUSP |
|
December 2003 |
December 2010 |
December 2014 |
April 17, 2006 |
January 18, 2017 |
|
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Ribeirão Preto, Brazil
|
|
| 43 |
NCT01540175 |
Completed |
Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant |
- Solid Tumor
- Brain Tumor
- Lymphoma
|
- Other: Blood samples obtained
|
Observational
|
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change in the immune reconstitution of T cell, B cell, and NK cell compartment.
|
31 |
All |
up to 21 Years (Child, Adult) |
NCT01540175 |
XPD12-013 IROPAST |
IROPAST |
March 2012 |
June 2015 |
June 2015 |
February 28, 2012 |
July 14, 2015 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
|
| 44 |
NCT00807651 |
Unknown † |
Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes |
|
- Procedure: AHSCT
- Drug: Insulin therapy
|
Interventional
|
Phase 2 |
- Shanghai Jiao Tong University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Exogenous insulin dose
- Anti-GAD titres
- C-peptide level
- HbA1c level
|
40 |
All |
14 Years to 35 Years (Child, Adult) |
NCT00807651 |
CCEMD006 |
|
February 2008 |
June 2016 |
December 2016 |
December 12, 2008 |
June 7, 2016 |
|
- Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai, China
|
|
| 45 |
NCT00230035 |
Withdrawn |
Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) |
- Systemic Lupus Erythematosus
|
- Procedure: Leukapheresis
- Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)
- Procedure: Autologous CD34+HPC transplantation (HSCT)
- (and 11 more...)
|
Interventional
|
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mortality resulting from treatment, underlying disease, or unrelated causes
|
0 |
All |
18 Years to 60 Years (Adult) |
NCT00230035 |
DAIT SCSLE-01 |
|
September 2005 |
|
|
September 30, 2005 |
February 1, 2013 |
|
- UCSD, Thornton Hospital
La Jolla, California, United States - UCLA, Rehabilitation Center
Los Angeles, California, United States - Northwestern University
Chicago, Illinois, United States - (and 2 more...)
|
|
| 46 |
NCT00957736 |
Terminated |
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant |
|
- Genetic: polymorphism analysis
- Other: laboratory biomarker analysis
|
Observational
|
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- To study the SNP profiles of a select group of candidate non-HLA genes among various cGVHD subtypes. Patients will be stratified as having classic cGVHD vs. non-classic GVHD for initial analyses.
- Correlation of SNP profiles with predominant organ involvement and responsiveness of cGVHD to therapy
- Correlation of SNP profiles with survival endpoints
|
252 |
All |
Child, Adult, Older Adult |
NCT00957736 |
VICC BMT 0867
P30CA068485
VU-VICC-BMT-0867
IRB# 080995 |
|
November 2008 |
December 2008 |
December 2008 |
August 12, 2009 |
May 14, 2013 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
|
| 47 |
NCT00278642 |
Terminated |
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders |
|
- Biological: Hematopoietic stem cell transplantation
|
Interventional
|
Phase 1 |
- Richard Burt, MD
- Northwestern University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent surface area involved New skin or mucosal blister development Immune suppressive medication requirements Survival
|
1 |
All |
18 Years to 60 Years (Adult) |
NCT00278642 |
DIAD Derm.Auto2001 |
|
September 2002 |
September 2011 |
September 2011 |
January 18, 2006 |
April 8, 2013 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 48 |
NCT01895439 |
Completed |
Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis |
|
- Biological: Autologous Mesenchymal Stem Cells
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The number of patients with any relevant side effects observed
- Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.
|
13 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01895439 |
MSUJCTC |
|
October 2012 |
February 2016 |
February 2016 |
July 10, 2013 |
May 2, 2017 |
|
- Cell Therapy Center, Jordan University Hospital
Amman, Jordan
|
|
| 49 |
NCT01690247 |
Unknown † |
Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance |
- Evidence of Liver Transplantation
|
- Drug: Conventional plus UC-MSC
- Drug: Conventional plus placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence rate of acute rejection and early liver function recovery
- Patient and graft survival, and prevalence of adverse events
|
50 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01690247 |
Beijing302-008 |
|
February 2012 |
February 2014 |
February 2015 |
September 21, 2012 |
May 31, 2013 |
|
- Beijing 302 Hospital
Beijing, China
|
|
| 50 |
NCT03326505 |
Recruiting |
Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment |
|
- Biological: Umbilical cord derived Mesenchymal Stem Cells
- Other: Supervised physical therapy
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Relevant adverse events will be observed
- Measuring Magnetic Resonance Imaging (MRI) outcomes of the treatment
- Measuring motor outcomes to assess treatment efficacy
- (and 2 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03326505 |
ALLOMSUJCTC |
|
September 25, 2017 |
May 2019 |
May 2020 |
October 31, 2017 |
October 31, 2017 |
|
- Cell Therapy Center, University of Jordan
Amman, Jordan - Cell Therapy Center
Amman, Jordan
|
|
| 51 |
NCT01453764 |
Withdrawn |
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis |
- Multiple Sclerosis
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
|
- Procedure: Harvesting and Implantation of SVF
|
Interventional
|
Not Applicable |
- Ageless Regenerative Institute
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical improvement in disability score compared to baseline
- Number of patients with adverse events
- MS disease activity measured by the number of Gd-enhancing brain MRI lesions
- Reduced number of relapses or freedom from progression of disease
|
0 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01453764 |
AD-US-MS-001 |
|
April 2016 |
December 2018 |
April 2019 |
October 18, 2011 |
September 1, 2017 |
|
- Ageless Regenerative Institute LLC
Aventura, Florida, United States
|
|
| 52 |
NCT01661842 |
Unknown † |
Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis |
|
- Other: conventional plus UC-MSC treatment
- Other: Conventional plus placebo treatment
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Liver Histology change
- Serum alanine aminotransferase (ALT)
- Serum AST
- (and 6 more...)
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01661842 |
Beijing302-006 |
|
October 2011 |
October 2014 |
October 2014 |
August 10, 2012 |
May 31, 2013 |
|
- Beijing 302 Hospital
Beijing, Beijing, China
|
|
| 53 |
NCT01445821 |
Recruiting |
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial |
|
- Biological: Peripheral Blood Stem Cells
- Drug: Cyclophosphamide
- Drug: Mesna
- (and 4 more...)
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Treatment Failure
- Survival
|
160 |
All |
17 Years to 60 Years (Child, Adult) |
NCT01445821 |
ASSIST IIb |
DIScl2011 |
September 2011 |
December 2018 |
September 2019 |
October 4, 2011 |
March 29, 2018 |
|
- Northwestern University
Chicago, Illinois, United States
|
|
| 54 |
NCT02975960 |
Completed |
ADMSCs for the Treatment of Systemic Sclerosis |
|
- Biological: injection of autologous stromal vascular fraction
|
Interventional
|
Not Applicable |
- The Catholic University of Korea
- Seoul St. Mary's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks
- Change from baseline Raynaud's condition score at 12 weeks
- Change from baseline Visual Analog Score for pain the hands at 12 weeks
- (and 6 more...)
|
7 |
All |
18 Years and older (Adult, Older Adult) |
NCT02975960 |
KC16TISI0343 |
|
October 25, 2016 |
October 30, 2017 |
January 20, 2018 |
November 29, 2016 |
January 25, 2018 |
|
- Seoul St. Mary's hospital
Seoul, Korea, Republic of
|
|
| 55 |
NCT02274662 |
Available |
Expanded Access Protocol Thymus Transplantation |
- Poor Thymic Function
- Immunodeficiency
- Athymia
- (and 3 more...)
|
- Biological: Thymus Transplantation
- Procedure: Blood Draw
- Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
|
Expanded Access
|
|
- M. Louise Markert
- Enzyvant Therapeutics GmbH
- Duke University
|
Other / Industry |
|
|
|
All |
Child, Adult, Older Adult |
NCT02274662 |
Pro00051692 |
|
|
|
|
October 24, 2014 |
January 16, 2019 |
|
|
|
| 56 |
NCT00028236 |
Completed |
Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) |
- Severe Combined Immunodeficiency
|
- Drug: Gene-Transduced Autologous CD34+ Stem Cells
|
Interventional
|
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
3 |
All |
18 Months to 20 Years (Child, Adult) |
NCT00028236 |
020057
02-I-0057 |
|
December 10, 2001 |
July 25, 2011 |
July 25, 2011 |
December 18, 2001 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 57 |
NCT02549586 |
Active, not recruiting |
Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance |
- Complication of Transplanted Organ, Nos
|
- Other: Autologous Hematopoietic Stem Cell Transplant
|
Interventional
|
Phase 2 |
- Gary A Levy, O. Ont. MD. FRCP AGAF
- Ottawa Hospital Research Institute
- University of Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients who develop tolerance post autologous HSCT
- HSCT mortality
- HSCT related morbidity
- Rate of immune reconstitution
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02549586 |
Tol 001 |
ASCOTT |
December 2015 |
December 2018 |
January 2020 |
September 15, 2015 |
May 15, 2018 |
|
- The Ottawa Hopital
Ottawa, Ontario, Canada - Multi-Organ Transplant Program, Toronto General Hospital
Toronto, Ontario, Canada
|
|
| 58 |
NCT01662973 |
Unknown † |
Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis |
- Primary Biliary Cirrhosis
|
- Other: conventional plus UC-MSC treatment
- Other: Conventional plus placebo treatment
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum alkaline phosphatase (ALP)
- Histological changes in liver biopsies
- Serum Bilirubin
- (and 5 more...)
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01662973 |
Beijing302-005 |
|
October 2011 |
October 2013 |
October 2013 |
August 13, 2012 |
May 31, 2013 |
|
- Beijing 302 Hospital
Beijing, Beijing, China
|
|
| 59 |
NCT03171194 |
Active, not recruiting |
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus |
- System; Lupus Erythematosus
|
- Drug: Low Dose Mesenchymal Stem Cells (MSCs)
|
Interventional
|
Phase 1 |
- Medical University of South Carolina
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of Grade 3 or higher adverse events
- Frequency of All Adverse Events
- Change in Disease Activity
- (and 6 more...)
|
6 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03171194 |
00061632 |
|
April 27, 2017 |
April 2019 |
April 2020 |
May 31, 2017 |
May 10, 2018 |
|
- Emory University
Atlanta, Georgia, United States - Medical University of South Carolina
Charleston, South Carolina, United States
|
|
| 60 |
NCT00472225 |
Unknown † |
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease |
- Steroid-Refractory Chronic GVHD
|
|
Interventional
|
Phase 2 |
- The Korean Society of Hematopoietic Stem Cell Transplantation
- Hoffmann-La Roche
- The Korean Society of Hematopoietic Stem Cell Transplantation
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response (CR) : Resolution of all signs and symptoms of chronic GVHD Partial response (PR) : Improvement (at least 1 clinical score reduction) in 1 or more organs of involvement and no evidence of worsening in any organ
- Steroid tapering
- Quality of life
- Toxicity
|
42 |
All |
3 Years to 74 Years (Child, Adult, Older Adult) |
NCT00472225 |
KHSCT-01-2007 |
|
May 2007 |
May 2008 |
May 2009 |
May 11, 2007 |
February 24, 2009 |
|
- Kyungpook University Hospital
Daegu, Kyungsang-do, Korea, Republic of - Busan Baik Hospital
Busan, Korea, Republic of - Busan National University Hospital
Busan, Korea, Republic of - (and 6 more...)
|
|
| 61 |
NCT03297177 |
Not yet recruiting |
Autologous Stem/Stromal Cells in Neurological Disorders and Disease |
- Dementia
- Parkinson
- Altered Behavior in Alzheimer Disease
- (and 3 more...)
|
- Procedure: Microcannula Harvest Adipose
- Device: Centricyte 1000
- Procedure: Sterile Normal Saline Infusion
|
Interventional
|
Not Applicable |
- Regeneris Medical
- Global Alliance for Regenerative Medicine
- Robert W. Alexander, MD, FICS
- Regeneris Medical Inc
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participant with adverse events (AE) or severe adverse events (SAE)
- Neurological Function
- Neurological Tested Functions
- Magnetic Resonance Imaging (MRI)
|
300 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT03297177 |
GARM NDD |
NDD |
January 1, 2020 |
January 1, 2023 |
January 1, 2023 |
September 29, 2017 |
October 18, 2018 |
|
- Regeneris Medical Inc
North Attleboro, Massachusetts, United States - Regeneris Medical
North Attleboro, Massachusetts, United States
|
|
| 62 |
NCT00787722 |
Active, not recruiting |
Hematopoietic Stem Cell Transplant in Devic's Disease |
|
- Procedure: Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: G-CSF
- (and 4 more...)
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival
- Visual Acuity
- Decreased weakness in limb (MRS)
- (and 7 more...)
|
13 |
All |
16 Years to 65 Years (Child, Adult, Older Adult) |
NCT00787722 |
DIAD Devic's Disease Auto 2008 |
|
October 10, 2009 |
August 2018 |
January 2019 |
November 7, 2008 |
July 17, 2018 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 63 |
NCT03562065 |
Not yet recruiting |
Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord |
- Lupus Erythematosus
- Stem Cell Transplant
|
- Biological: mesenchymal stem cells
|
Interventional
|
Phase 1
Phase 2 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity of allogeneic MSC injection according to CTCAE
- Toxicity of allogeneic MSC injection according to CTCAE Month 1
- Toxicity of allogeneic MSC injection according to CTCAE Month 3
- (and 34 more...)
|
10 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03562065 |
P150302 |
MSC-SLE |
July 1, 2018 |
June 1, 2021 |
June 1, 2021 |
June 19, 2018 |
June 19, 2018 |
|
- Saint-Louis Hospital
Paris, France
|
|
| 64 |
NCT03829566 |
Recruiting
New |
Autologous Transplant To End NMO Spectrum Disorder |
- Neuromyelitis Optica
- Devic's Disease
- NMO Spectrum Disorder
|
- Drug: Rituximab
- Drug: Cyclophosphamide
- Drug: Mesna
- (and 5 more...)
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival
- Relapse-Free Survival
- Expanded Disability Status Scale (EDSS) Improvement
- (and 7 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03829566 |
DIAD.ATTEND.2018 |
ATTEND |
March 2019 |
January 1, 2025 |
January 1, 2026 |
February 4, 2019 |
February 4, 2019 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States - Northwestern University
Chicago, Illinois, United States
|
|
| 65 |
NCT00342134 |
Completed |
Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis |
|
- Procedure: Stem Cell Transplanataion
|
Interventional
|
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
34 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00342134 |
999902196
02-N-N196 |
|
May 1, 2002 |
May 4, 2011 |
May 4, 2011 |
June 21, 2006 |
July 2, 2017 |
|
- Northwestern University
Chicago, Illinois, United States - Johns Hopkins University
Baltimore, Maryland, United States
|
|
| 66 |
NCT00001630 |
Completed |
Treatment of Autoimmune Thrombocytopenia (AITP) |
- Autoimmune Disease
- Autoimmune Hemolytic Anemia
- Thrombocytopenia
|
|
Interventional
|
Phase 1 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
29 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00001630 |
970154
97-H-0154 |
|
July 21, 1997 |
|
June 11, 2009 |
November 4, 1999 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 67 |
NCT01953523 |
Completed |
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions |
- Neurodegenerative Diseases
- Osteoarthritis
- Erectile Dysfunction
- (and 3 more...)
|
- Procedure: Administration of autologous adipose derived SVF
|
Interventional
|
Not Applicable |
- Elliot Lander
- Cell Surgical Network Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with adverse events
- Changes in the Oswestry Disability Index
- Changes in the Neck Disability Index
- (and 9 more...)
|
3000 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT01953523 |
CSN111 |
|
September 2, 2013 |
December 31, 2016 |
January 1, 2017 |
October 1, 2013 |
September 25, 2018 |
|
- California Stem Cell Treatment Center
Rancho Mirage, California, United States
|
|
| 68 |
NCT01347346 |
Completed |
Gene Therapy for WAS |
|
- Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
|
Interventional
|
Phase 1
Phase 2 |
- Genethon
- Hôpital Necker-Enfants Malades
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in the eczema status
- Reduction in the frequency and severity of infection episodes
- Reduction in the frequency and severity of bruising and bleeding episodes
- (and 9 more...)
|
5 |
Male |
Child, Adult, Older Adult |
NCT01347346 |
GTG003.08
2009-011152-22 |
|
May 2011 |
January 13, 2016 |
January 9, 2017 |
May 4, 2011 |
May 22, 2018 |
|
- Hôpital Necker-Enfants Malades
Paris, France
|
|
| 69 |
NCT01347242 |
Recruiting |
Gene Therapy for Wiskott-Aldrich Syndrome (WAS) |
|
- Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
|
Interventional
|
Phase 1
Phase 2 |
- Genethon
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Institute of Child Health
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in the eczema status
- Reduction in the frequency and severity of infection episodes
- Reduction in the frequency and severity of bruising and bleeding episodes
- (and 9 more...)
|
5 |
Male |
Child, Adult, Older Adult |
NCT01347242 |
GTG002.07 |
|
March 2011 |
December 2019 |
December 2019 |
May 4, 2011 |
May 21, 2018 |
|
- Great Ormond Street Hospital
London, United Kingdom - Royal Free Hospital
London, United Kingdom
|
|
| 70 |
NCT00278590 |
Withdrawn |
Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus |
- Systemic Lupus Erythematosus
|
- Biological: Allogeneic Stem Cell Transplantation
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival, disease free survival, number of relapses, organ function
|
0 |
All |
18 Years to 50 Years (Adult) |
NCT00278590 |
DI SLE.Allo2004 |
|
July 2004 |
July 2015 |
July 2015 |
January 18, 2006 |
January 13, 2017 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 71 |
NCT01519141 |
Active, not recruiting |
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection |
|
|
Observational
|
|
- University of California, San Francisco
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- carotid intima-media thickness
- brachial artery flow-mediated dilatation
- D-dimer
|
400 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01519141 |
R01HL095130
5R01HL095130 |
|
July 2003 |
June 2019 |
June 2020 |
January 26, 2012 |
December 12, 2018 |
|
- University of California San Francisco, San Francisco General Hospital
San Francisco, California, United States
|
|
| 72 |
NCT00278486 |
Terminated |
Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON) |
|
- Biological: Hematopoietic stem cell transplantation.
|
Interventional
|
Phase 1 |
- Richard Burt, MD
- Northwestern University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Standard Snellen acuity clinical testing and improvement visual fields is done by using Humphrey Automated Machine with 30-2 program or using Kinetic Visual Fields on the Goldman Perimeter)
|
2 |
All |
18 Years to 60 Years (Adult) |
NCT00278486 |
DI ARRON 04 |
|
August 2004 |
April 2012 |
April 2012 |
January 18, 2006 |
April 8, 2013 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 73 |
NCT02633163 |
Recruiting |
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) |
- Systemic Lupus Erythematosus
|
- Drug: Low Dose Mesenchymal Stem Cells (MSCs)
- Drug: High Dose Mesenchymal Stem Cells (MSCs)
- Drug: Placebo Infusion
|
Interventional
|
Phase 2 |
- Medical University of South Carolina
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Clinical response at Week 24 as defined by the SLE Responder Index (SRI):
- Change in SLEDAI score between groups
- Renal and non-renal organ system flares
- (and 9 more...)
|
81 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02633163 |
MUSC-UCMSC-001 |
|
October 26, 2018 |
June 2021 |
June 2021 |
December 17, 2015 |
February 5, 2019 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States - University of California - San Diego
San Diego, California, United States - Emory University
Atlanta, Georgia, United States - (and 4 more...)
|
|
| 74 |
NCT03219801 |
Not yet recruiting |
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus |
- Systemic Lupus Erythematosus
|
- Biological: mesenchymal stem cells
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change of Complement levels(C3 and C4) in peripheral blood
- Erythrocyte sedimentation rate
- C-reactive protein
- adverse reaction
|
10 |
All |
14 Years to 60 Years (Child, Adult) |
NCT03219801 |
17277787D-SLE |
|
August 1, 2017 |
December 30, 2018 |
December 30, 2019 |
July 18, 2017 |
July 18, 2017 |
|
- the First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
|
|
| 75 |
NCT01415726 |
Completed |
Stem Cell Educator Therapy in Type 2 Diabetes |
|
- Device: Stem Cell Educator
|
Interventional
|
Phase 1
Phase 2 |
- University of Illinois at Chicago
- Chinese government
- Jinan Tianhe Stem Cell Biotechnologies Co Ltd
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Inflammation control
- Metabolic control
|
25 |
All |
14 Years to 65 Years (Child, Adult, Older Adult) |
NCT01415726 |
2011-010 |
|
July 2011 |
February 2012 |
February 2012 |
August 12, 2011 |
February 17, 2012 |
|
- General Hospital of Jinan Military Command
Jinan, Shandong, China
|
|
| 76 |
NCT01836289 |
Withdrawn |
High-dose Cyclophosphamide for Severe Refractory Crohn Disease |
- Crohn's Disease
- Crohn Disease
|
- Drug: High-dose Cyclophosphamide
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluation of safety of the High-Dose Cyclophosphamide (HDC) protocol
- HDC-Induced Steroid-free remission
- HDC-Induced Mucosal Healing
- (and 2 more...)
|
0 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT01836289 |
NA_00052668 |
|
March 2015 |
March 2018 |
March 2018 |
April 19, 2013 |
August 13, 2018 |
|
|
|
| 77 |
NCT00750971 |
Recruiting |
Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST) |
- Systemic Lupus Erythematosus
|
- Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
|
Interventional
|
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- SLEDAI
- Serologic response (autoantibodies)
- Immune Reconstitution
- Organ-specific response parameters
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT00750971 |
CT-1306 |
ASSIST |
August 2008 |
July 2020 |
August 2020 |
September 11, 2008 |
March 20, 2017 |
|
- Universitätsmedizin Charité
Berlin, Germany - Universitätsklinik Düsseldorf
Düsseldorf, Germany - Universitätsklinikum Essen
Essen, Germany - (and 5 more...)
|
|
| 78 |
NCT03292263 |
Recruiting |
ASCT With Nivolumab in Patients With Multiple Myeloma |
|
- Drug: Melphalan
- Drug: Nivolumab
- Procedure: Autologous Stem Cell Transplantation
|
Interventional
|
Phase 1
Phase 2 |
- St. Petersburg State Pavlov Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response
- Progression free survival (PFS)
- Overall Survival (OS)
- Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03
|
30 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03292263 |
11/17-n |
|
April 24, 2017 |
April 2019 |
April 2021 |
September 25, 2017 |
September 25, 2017 |
|
- Boris V Afanasyev, MD, Prof.
Saint Petersburg, Russian Federation
|
|
| 79 |
NCT01161628 |
Completed
Has Results |
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) |
- Chronic Graft-versus-host Disease
|
|
Interventional
|
Phase 2 |
- Northside Hospital, Inc.
- Blood and Marrow Transplant Group of Georgia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Complete Response of cGVHD to Treatment.
- Rate of Overall Response of cGVHD to Treatment
- Rate of Partial Response of cGVHD to Treatment
- (and 6 more...)
|
25 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01161628 |
NSH 893 |
|
April 2011 |
January 2014 |
July 2015 |
July 13, 2010 |
April 20, 2016 |
February 24, 2016 |
- Northside Hospital
Atlanta, Georgia, United States
|
|
| 80 |
NCT00092235 |
Recruiting |
Factors Determining Outcomes in Patients With Graft-Versus-Host Disease |
- Chronic Graft vs Host Disease
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To establish a multidisciplinary clinic infrastructure for study of pathogenesis and natural history of cGVHD
- To prospectively identify candidate markers for clinical and biological prognostic factors in patients with cGVHD and develop a prognostic model
- To develop clinically relevant cGVHD grading scales
- (and 3 more...)
|
550 |
All |
1 Year to 75 Years (Child, Adult, Older Adult) |
NCT00092235 |
040281
04-C-0281 |
|
September 20, 2004 |
|
|
September 22, 2004 |
February 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Hackensack University Medical Center
Hackensack, New Jersey, United States
|
|
| 81 |
NCT00271934 |
Completed |
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study |
- Systemic Lupus Erythematosus
|
- Biological: Immune ablation and hematopoietic stem cell support.
|
Interventional
|
Phase 2 |
- Richard Burt, MD
- Northwestern University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
52 |
All |
up to 60 Years (Child, Adult) |
NCT00271934 |
NU95LU1 |
|
September 2002 |
November 2007 |
April 2012 |
January 4, 2006 |
April 11, 2012 |
|
- Northwestern University, feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 82 |
NCT01394640 |
Completed |
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients |
- Lymphoma
- Multiple Myeloma
- Myeloproliferative Disease
|
- Biological: Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
|
Observational
|
|
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- University of Milan
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To assess antibody response (antibody titer > 1:40 or four-fold increase, geometric mean titer) in onco-hematologic patients and controls and whether this response changes over time
- To assess virus specific cell mediated response (by flow-cytometry evaluation) in onco-hematologic patients and controls and whether this response changes over time.
- To assess whether controls or patients develop influenza like illness or symptoms.
|
124 |
All |
18 Years and older (Adult, Older Adult) |
NCT01394640 |
INT 72/09 |
|
October 2009 |
May 2010 |
January 2011 |
July 14, 2011 |
August 1, 2011 |
|
- Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
|
|
| 83 |
NCT03602599 |
Recruiting |
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls |
- Graft Versus Host Disease
|
|
Observational
|
|
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
500 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03602599 |
180121
18-D-0121 |
|
November 15, 2018 |
May 31, 2023 |
May 31, 2023 |
July 27, 2018 |
November 20, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 84 |
NCT02835547 |
Completed |
Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN) |
- Inflammatory and Acquired Dysimmune Diseases
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The occurrence of any cardiovascular event (will be recorded from the patient files and/or phone calls to patient")
|
600 |
All |
18 Years and older (Adult, Older Adult) |
NCT02835547 |
D50841 |
CARMIN |
February 2009 |
August 2015 |
August 2015 |
July 18, 2016 |
July 18, 2016 |
|
|
|
| 85 |
NCT00698191 |
Unknown † |
Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE) |
- Refractory Systemic Lupus Erythematosus
|
- Biological: Allogeneic MSC (AlloMSC)
|
Interventional
|
Phase 1
Phase 2 |
- Nanjing Medical University
- National Natural Science Foundation of China
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
- Lupus serology (ANA, dsDNA, C3, C4)
- Renal function (GFR, BUN, urinalysis)
- Percentage of systemic T regulatory population
|
20 |
All |
15 Years to 70 Years (Child, Adult, Older Adult) |
NCT00698191 |
NSFC30772014 |
|
March 2007 |
December 2011 |
December 2012 |
June 17, 2008 |
June 17, 2008 |
|
- Department of Rheumatology and Immunology, Nanjing University Medical College Affiliated Drum Tower Hospital
Nanjing, Jiangsu, China
|
|
| 86 |
NCT02000362 |
Unknown † |
Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD) |
|
|
Interventional
|
Phase 1
Phase 2 |
- Kang Stem Biotech Co., Ltd.
- Kang Stem Biotech Co., Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events, Ratio of patients who is applicable to CDAI<150
- the ratio of patients who reduce CDAI over 70 as contrasted with baseline value
- a variation of CRP value as contrasted with baseline
- (and 6 more...)
|
24 |
All |
19 Years to 70 Years (Adult, Older Adult) |
NCT02000362 |
KSTHD_FURESTEM-CD |
|
August 2014 |
September 2018 |
October 2018 |
December 4, 2013 |
September 6, 2017 |
|
- Inje University Haeundae Paik Hospital
Busan, Korea, Republic of - Yeungnam University Medical Center
Daegu, Korea, Republic of - Seoul National Universtiy Bundang Hospital
Seongnam-si, Korea, Republic of - (and 4 more...)
|
|
| 87 |
NCT00278616 |
Withdrawn |
Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome |
- ANTIPHOSPHOLIPID SYNDROME
|
- Biological: Stem Cell Transplantation
|
Interventional
|
Phase 1 |
- Richard Burt, MD
- Northwestern University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity; Survival;Disease improvement;Time to disease progression;
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT00278616 |
NU APS AUTO 2004 |
|
August 2005 |
October 2011 |
October 2011 |
January 18, 2006 |
April 11, 2012 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
|
| 88 |
NCT02495766 |
Active, not recruiting |
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis |
- Relapsing-Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
|
- Drug: XCEL-MC-ALPHA
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Banc de Sang i Teixits
- Vall d'Hebron Research Institute (VHIR)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Adverse events
- Cumulative number of MRI Gd-enhancing lesions
- Multiple Sclerosis Outbreaks
- (and 2 more...)
|
8 |
All |
18 Years to 60 Years (Adult) |
NCT02495766 |
XCEL-MS-02 |
EMMES |
May 11, 2015 |
November 27, 2017 |
June 2020 |
July 13, 2015 |
July 3, 2018 |
|
- Hospital Vall Hebron
Barcelona, Spain
|
|
| 89 |
NCT01377870 |
Completed |
Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis |
|
- Biological: intravenous injection of mesenchymal stem cells
- Biological: injection of cell free media
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MRI metrics changes
- Brain atrophy
- number of sever relapses
- (and 5 more...)
|
22 |
All |
18 Years to 55 Years (Adult) |
NCT01377870 |
Royn-nerve-001 |
|
December 2011 |
March 2014 |
April 2014 |
June 21, 2011 |
March 7, 2018 |
|
- Royan Institute
Tehran, Iran, Islamic Republic of
|
|
| 90 |
NCT00325741 |
Unknown † |
Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus |
- Lupus Erythematosus, Systemic
|
- Procedure: Hematopoietic Cell Transplantation
|
Interventional
|
Phase 1 |
- National Heart, Lung, and Blood Institute (NHLBI)
- City of Hope National Medical Center
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to achieve complete remission (participants that are off all immunosuppressive therapy without clinical or laboratory evidence of active disease)
- Percentage of patients with stable chimerism in all blood and immune cell lineages
- Percentage of participants with acute or chronic graft-versus-host disease
|
15 |
All |
18 Years to 64 Years (Adult) |
NCT00325741 |
368
P01HL075462-02 |
|
June 2004 |
July 2010 |
July 2010 |
May 15, 2006 |
August 7, 2009 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
|
| 91 |
NCT00920218 |
Completed
Has Results |
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A |
|
- Biological: Herpes Zoster Vaccine 1437173A
- Biological: Placebo vaccine (saline)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
- Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs)
- (and 11 more...)
|
121 |
All |
18 Years and older (Adult, Older Adult) |
NCT00920218 |
110258 |
|
July 14, 2009 |
April 26, 2011 |
March 21, 2012 |
June 15, 2009 |
December 12, 2017 |
December 12, 2017 |
- GSK Investigational Site
Little Rock, Arkansas, United States - GSK Investigational Site
Duarte, California, United States - GSK Investigational Site
Frisco, California, United States - (and 8 more...)
|
|
| 92 |
NCT00501995 |
Completed
Has Results |
High Dose Cyclophosphamide for Treatment of Scleroderma |
|
- Drug: IV Cyclophosphamide
|
Interventional
|
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in the Modified Rodnan Skin Score.
- Change in the HAQ-DI, PGA, FVC and DLCO
|
6 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00501995 |
00-11-17-02 |
|
February 2001 |
July 2008 |
May 2010 |
July 17, 2007 |
June 14, 2017 |
July 2, 2014 |
|
|
| 93 |
NCT01741857 |
Unknown † |
Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus |
- Systemic Lupus Erythematosus
|
- Biological: human umbilical cord derived MSC transplantation for SLE
|
Interventional
|
Phase 1
Phase 2 |
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- British Isles Lupus Assessment Group score (BILAG)
- Lupus serology (Alb, ANA, dsDNA, C3, C4)
- Renal function (GFR, Blood Urea Nitrogen, urinalysis)
|
40 |
All |
15 Years to 60 Years (Child, Adult) |
NCT01741857 |
NJGLYY005 |
|
January 2012 |
December 2013 |
December 2013 |
December 5, 2012 |
November 5, 2013 |
|
- The Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
|
|
| 94 |
NCT02851056 |
Suspended |
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) |
|
- Biological: Survivin Vaccine
- Procedure: Autologous Hematopoietic Cell Transplantation
- Biological: Prevnar 13
- Drug: Granulocyte-colony Stimulating Factor
|
Interventional
|
Early Phase 1 |
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Complete Response (CR)
- Number of Participants With Treatment Emergent Adverse Events
- Number of Participants With Improved Immunologic Response
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02851056 |
MCC-18346 |
|
August 26, 2016 |
September 2019 |
September 2020 |
August 1, 2016 |
January 4, 2019 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 95 |
NCT01964625 |
Terminated |
Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD) |
- Chronic Graft Versus Host Disease
|
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To determine ability of PET-CT scans to delineate and stage initial chronic GvHD
- To determine ability of PET-CT scans to document response to chronic GvHD therapy
|
1 |
All |
18 Years and older (Adult, Older Adult) |
NCT01964625 |
32186 |
|
November 2010 |
August 2013 |
August 2013 |
October 17, 2013 |
October 17, 2013 |
|
- University of Rochester Medical Center
Rochester, New York, United States
|
|
| 96 |
NCT03593902 |
Recruiting |
Cardiac Safe Transplants for Systemic Sclerosis |
- Systemic Sclerosis
- Scleroderma
|
- Drug: Rituximab
- Drug: Fludarabine
- Drug: Cyclophosphamide
- (and 6 more...)
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in skin score by mRSS
- Change in FVC on pulmonary function test
- Treatment related mortality
- (and 11 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03593902 |
DIAD.CAST.2018 |
CAST |
September 7, 2018 |
January 2025 |
January 2026 |
July 20, 2018 |
September 12, 2018 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States - Northwestern University
Chicago, Illinois, United States
|
|
| 97 |
NCT01036958 |
Completed |
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease |
- Chronic Graft-Versus-Host-Disease
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Develop pediatric cGVHD symptom scale
- Rasch measurement model, determine sensitivity to use in clinicalintervention trials
- Correlate scores with QOL measures
|
3 |
All |
5 Years to 18 Years (Child, Adult) |
NCT01036958 |
100019
10-C-0019 |
|
November 25, 2009 |
|
February 6, 2018 |
December 21, 2009 |
September 26, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 98 |
NCT00989547 |
Unknown † |
Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM) |
|
- Other: Umbilical Cord Blood VITA 34
|
Interventional
|
Phase 1 |
- Technische Universität München
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- insulin production
- Insulin Dose, Autoantibody levels, T-cell functional response assays, Cytokine levels
|
18 |
All |
1 Year and older (Child, Adult, Older Adult) |
NCT00989547 |
593 |
|
September 2008 |
September 2014 |
|
October 5, 2009 |
July 23, 2013 |
|
- Forschergruppe Diabetes der Technischen Universität
München, Bavaria, Germany
|
|
| 99 |
NCT03390231 |
Recruiting |
Stem Cell Educator Therapy in Diabetes |
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
|
- Combination Product: Stem Cell Educator therapy
|
Interventional
|
Phase 2 |
- Tianhe Stem Cell Biotechnologies Inc.
- Chinese PLA General Hospital
- Tianhe Stem Cell Biotechnologies Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes of inflammation-related markers in diabetic patients after Stem Cell Educator therapy
- Change in insulin resistance
- Metabolic control in HbA1C levels
- (and 2 more...)
|
100 |
All |
20 Years to 60 Years (Adult) |
NCT03390231 |
S2017-059-01 |
|
November 27, 2017 |
December 30, 2020 |
December 31, 2020 |
January 4, 2018 |
February 5, 2019 |
|
- Department of Endocrinology, Chinese PLA General Hospital
Beijing, China
|
|
| 100 |
NCT03421548 |
Withdrawn |
Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1 |
- Glaucoma
- Blindness, Acquired
- Keratitis, Herpetic
- (and 4 more...)
|
|
Interventional
|
Not Applicable |
- Centre hospitalier de l'Université de Montréal (CHUM)
- Implandata Ophthalmic Products GmbH
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IOP data gathering
- Relationship between IOP data and determinants factors of glaucoma
- Safety and tolerability of the EyeMate sensor
|
0 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03421548 |
2016-6261 |
BKPro |
November 2016 |
January 2020 |
June 2020 |
February 5, 2018 |
February 5, 2018 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: